- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Prioritised
- Prioritisation programme:
- Medicines evaluation
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- Prioritisation Board agreed that criteria 1 and 4 of the highly specialised technology framework were not met (see NICE-wide topic prioritisation: the manual), and that therefore the treatment should be routed to the technology appraisals programme.
- Process:
- STA Standard
- ID number:
- 6453
Provisional Schedule
- Draft guidance:
- 08 May 2026 - 01 June 2026
- Committee meeting: 2:
- 17 June 2026
- Expected publication:
- 05 August 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- SpringWorks Therapeutics (Nirogacestat)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Sarcoma UK
- Professional groups
- Association of Cancer Physicians
- Association of Coloproctology of Great Britian and Ireland
- Cancer Research UK
- Royal College of Physicians
- Comparator companies
- Amarox (imatinib mesilate) (not participating)
- Bayer (sorafenib tosilate) (not participating)
- Cipla (imatinib mesilate) (not participating)
- Dr Reddy’s Laboratories (imatinib mesilate) (not participating)
- Grindeks Kalceks (imatinib mesilate) (not participating)
- Novartis Pharmaceuticals (pazopanib hydrochloride, imatinib mesilate) (not participating)
- Orion Pharma (imatinib mesilate) (not participating)
- Sandoz (sorafenib tosilate, imatinib mesilate) (not participating)
- Thornton & Ross (sorafenib tosilate) (not participating)
- Zentiva (sorafenib tosilate) (not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 April 2026 | Committee meeting: 1 |
| 15 April 2026 | Declaration of interests |
| 29 December 2025 | Note added to the project documents |
| 11 July 2025 | Invitation to participate |
| 16 April 2025 - 19 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6453 |
| 16 April 2025 | In progress. Scoping commenced. |
| 12 December 2024 | Referral |
| 30 May 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 May 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual